Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 6Leukemia, Myeloid, Acute 6Leukemia 4Carcinoma 3Hematologic Diseases 2Small Cell Lung Carcinoma 1Sarcoma, Myeloid 1Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1Acute Disease 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 41Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × vosaroxin × Clear all
NCT00252382 2018-09-24

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

Sunesis Pharmaceuticals

Phase 2 Completed
31 enrolled 6 charts
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡